triggering completed In million I the Good the we numerous DISSOLVE Kevin. proprietary made milestone Sobi. morning. notably, milestones. achieved everyone obligation on us our appreciate of $XX trial, second progress from the of quarter June key payment taking to XXXX, today. and you, II pipeline Thank across time enrollment a steady the join XX, Most we
receiving resulted in QX muscular preclinical and and million the agreement therapy of obligations for events dystrophy muscular Our in ImmTOR by These $X their XXXX. option June, anticipate limb-girdle in Duchenne that nine dystrophies milestones. combination continue from achieved gene partners and license certain Sarepta total extended subtypes their payment in Sarepta months progress with to two And we certain candidates. platform
priced Finally, XXXX, cash, cash fund cash X, approximately raising enable as $XX.X into XX, our June us that we restricted on offering, operations and April to an million. marketable of our will believe We securities existing equivalents, underwritten mid-XXXX.
of with will the an Selecta our half year second in be completing trial time as collaboration for Sobi. The III this important partner anticipate DISSOLVE Phase we
We announce to from in top XXXX. expect joint data line DISSOLVE QX
proprietary Phase track MMA, fourth clinic, gene We acidemia, our I to the or this the therapy treat year. also trials to into commence in clinical anticipate on remain we advancing methylmalonic of the SEL-XXX, candidate and quarter
Our the unlock advance for and therapy of tolerance autoimmune protease into studies selection pipeline, team to power development which protease, in the scale-up, our IND-enabling the manufacturing IgG precision and Ginkgo treatment efficacy partners therapies. gene IgA IGAN Biosciences re-imagine to our with and of most Bioworks therapies. potential of we Xork, an the is continues mid-XXXX, evolution antigen-specific for the proprietary believe are candidate amplify ImmTOR-IL, immunotherapy unlock of biologic financial runway platform. and well-positioned the notably to of gene disease, accelerating preclinical our of IgA we With AAV help expected our immune nephropathy
symptoms from the through amassing utilize the of Over pipeline. key all which recent standards million current care malignancies our diseases. or walk me address which underlying to Let XX drugs, patients leave to often serious now you of autoimmune infections disease. three across of cause treatments fail immunosuppressive some suffer pillars the highlights activities and The of vulnerable and Americans
T-cells precision autoimmune system immune restore Through we balance inducing regular expanding addressing our by underlying of Tregs disease. re-imagines the and immune by in hope antigen-specific approach Our paradigm platform, the vivo. tolerance treatment cause to or
preclinical recent selective ImmTOR. a of about synergistic of excited to very Tregs, IL-X platform for we're that when accelerating have a engineered is and data before, generated, combine XXXX in is for IL-X call proprietary with molecules development showing a activity the we are engineered combined substantial we A priority highlighted top Selecta evolution ImmTOR we've As ImmTOR-IL. with
of have We combine the development mutein that differentiated Biotechnology, using protein of Tregs our ImmTOR. spun programs selective autoimmune on those engineering pathogenesis technology in diseases. and to first-in-class antigen-specific like facilitate auto-antigens We Cyrus is the with focus IL-X potential for ImmTOR-IL of molecules be with to focused ImmTOR of Washington, treatment our on when partnered Baker's interest out Tregs, David for autoimmune combined diseases. next-generation, the with lab a a to highly truly of company responsible of and of at world-leading expansion other specific And IL-X believe University generalized engineered induction Tregs development antigen expansion has to differentiated
liver ducts. evaluate indication tolerance a autoimmune cholangitis, In disease, antigen PDC-EX. a first by which in The immune bile mistakenly in and platform biliary immune system precision our the PBC, in the mediated damage attacks or PBC, plan we driven the to primary small tissue well-defined T-cell is liver
need. progression treatments restore may XX% PDC-EX unmet limited of Tregs patients to PBC and or balance. intolerant of PBC and to prevent system While patients treatment treatments, are leaving not these do implicated in immune alternative the in ImmTOR-IL options expansion XX% autoantigen slow and complications result to a help to with with respond Co-administering approximately are in the the to specific significant PDC-EX, available,
toward expand additional to into we autoimmune and other selection, work plan indications. indication to continue We
updates provide ImmTOR-IL in development to expect for We the path our strategic future. near on
trial therapy a of body MMA. benefits pointing of metabolic disease We ImmTOR build enhancing we the safety of MMA-XXX Now trial for I of Phase ability our evidence combination AAV AAV and in will and to this AAV rare potentially with the the antibodies the safety down our MMA-XXX treatment treating certain in the and multifaceted cannot hope which and moving I being ImmTOR's neutralizing fats. growing ImmTOR, MMA Phase is of to body on SEL-XXX trial In XXXX, developed efficacy gene gene a starting pipeline. proteins in towards the The MMA break therapies. evaluate therapy QX a SEL-XXX, efficacy will on of anticipate mitigate against capsid. gene of
showcased Additionally, development an future past three Society could AskBio. clinical potentially for important therapy current from presentations, safer partnership This regulatory Cell from American Gene and patients the rare Selecta & partners, blueprint our provide and of AAV development the therapies accelerating of gene suffering including of with genetic Therapy, and our diseases. for SEL-XXX May, six at redoseable gene
abstract vector Award to potential effect would after observed ImmTOR data to this, to antibodies human combined Mutein over multiple durable redosing proof-of-concept human CSO, problem the ImmTOR-IL of a This the Building of ability and to Our AAV titrate we associated be with Kei the was vector the and for patients suggest antibodies doses of that considered risks done of to of observed demonstrated to with ImmTOR-IL report his AAVX-SEAP using solve demonstrated gene gene has vector could we for we titled of paradigm ImmTOR this with therapy days, anti-AAV doses Tolerogenic treatment that from in Anti-AAV the and whereby therapeutic XXX therapies avoid of monthly associated Antibodies. neutralizing anti-AAV transform showed doses formation and these four dose XXx today on up our higher and a dose doses mice or plus of and doses preclinical Inhibits Kishimoto, XEXX formation believe volunteers the receive Outstanding immune gene of with multiple tolerance inhibition ability days. Notably, low Poster model. where study mice Formation treatment and to This the sub-therapeutic ImmTOR study, gene slow, are ImmTOR's Presentation prior a therapy from produced needed of in IL-X IL-X days. studies. was mitigation out When through new studies antibody therapy in co-administered to onetime-only had of XXX gene in doses healthy inhibit alone. the single gene poster one results AAV durable complete to pleased benefit Combination an therapy of co-administered therapy Synergistically awarded Nanoparticles a induce vg/kg XX
facing the patient promise potentially a during as population to be Currently, need inclusion treatment anti-AAV gene are which which antibodies, to shown for therapy ineligible to a administered. are access IgG of create Thus antibodies may neutralizing natural trials accessibility. could one are be preexisting transiently no window AAV there and of XX% or modality for challenge alternatives. of life-altering XX% gene utilizing therapies clear in have result therapies therapy proteases key Another unable infections. a is and pretreatment for which patients due few gene to preexisting many
bacteria from themselves derived are However, IgG proteases immunogenic. are highly and
our And majority proteases pre-existing against a optimized cleave has IgG Additionally, common human individuals IgG, of low but nonhuman to from believe proteases. been some enzyme dosing human vast antibodies. repeat the IgG that combination are pathogen. Xork, pathogen, ImmTOR preexisting and activity could we protease from specifically the Xork observed proprietary of is have of candidate, derived antibodies consequently, these We cross have therapy. enable a derived anti-IgG protease to this with
and therapy studies discuss Xork how could with modality. a to for scale-up. the continue we moment to We important gene manufacturing want I be believe IND-enabling take
preexisting protecting natural by their population, the most are therapeutic therapies. Unfortunately, open are other diseases, de same those options. time, for facing gene Xork commercial not gene window ineligible could by the enable multipronged option. gene a for with bring novo of immunogenicity potential eligible ImmTOR-IL maximize therapy of treatment At For infections, taking redosing have hope to a due formation those represent to approach to treatment using genetic and for patients who effective and challenges to to antibodies have treatment patients, the to anti-AAV and candidates. antibodies. therapies. Xork By patients may we companies due the we to AAV many any therapy rare the can patients the gene the gene therapy patient neutralizing AAV promising mitigate increasing who, ImmTOR many treatment these We're help potential address ineligible
the for We Xork. therapy development by promise goal the continue and gene actively an the to pursuing platform opportunities true our our of business maximize of industry-leading ImmTOR gene toward providing of of value platform out-licensing capable unlocking to We both and therapies. toolbox plan AAV progress
which response believe and to platform on be a clinical pegadricase biologics dosed develop of update an development patients We adverse provide Many who an after with Patients our was for Sobi with a as chronic in the use of has to may forced biologics biologics of of suboptimal to precision immune immunogenic, want a approximately proof due treatment treatments. highly SEL-XXX, promising of patient reactions. XXXX. pipeline, multiple the with concept believe starting to refractory the uricase, to immune to offers we SEL-XXX antibodies be responses improve date. I ImmTOR reduce antidrug gout response approach an to immune in proprietary Lastly, co-administered or as XXX discontinue resulting can served ImmTOR and licensed experience outcomes. this treatment comprised is adjunct for tolerance
DISSOLVE at X.X announced mg in III enrollment of evaluated kg, Europe at of four XXXX, for two DISSOLVE single and third States, Our of with two In the with Phase per the XXX the and across which we States. picked United subjects mg and DISSOLVE consists up mg December enrollment SEL-XXX X, XXXX SEL-XXX. quarter dose Eastern of placebo-controlled levels conducted trials X.XX per I X.X recently enrolled XXX clinical being both of we of trials, United patients and countries ImmTOR, level program for kg. dose is closed kg being in pegadricase On II, double-blind per a in full is
advance enrollment II we reminder, and ongoing target XXXX payment our to towards to to track successful II of with partner, program. XXX trial a on in triggered $XX complete completion Sobi, full our subject discontinuations Achievement in authorities QX regulatory work subjects DISSOLVE of plan mitigate studies both to providers the Sobi, events DISSOLVE We of increased and joint top anticipated QX Ukraine. in million with a As enrollment remain due obligation from to from clinical geopolitical any we DISSOLVE closely the XXXX. and Russia line data in
called potential III, the our learnings leverage Phase with to kidneys. in Current nephropathy, that biologics derisked an impact improve approach, believe and protease, the With a biologics to occurs the IgAX have or pipeline a is underlying address in into IgA IgAX kidney the complexes transformative deposits, well-positioned patients' on of ImmTOR immunoglobulin is Selecta kidneys, pathophysiology treatments is of mechanistically IgA believe extensive has move currently function fail to protein the of disease. our the lives. when antibody which clinical data and combines our from which the indications second immune these AX injurious novel SEL-XXX We in disease IgA and renal an we accumulate markers
We selection by an our IgA with the across pipeline run over the that, external through June working call XXXX about partners of to results candidate pillars Kevin? second for and Kevin finalize milestones I'll extremely XX, advancements half are this protease clinical the all beyond. turn currently to XXXX. excited three value-driving and hope the program our year-end. in quarter identify our for the candidate of second ended to With We're to financial and
